• In the past week, Biogen Inc. announced it has gained exclusive worldwide rights to Vanqua Bio’s preclinical oral C5aR1 antagonist in a deal potentially worth over US$1 billion, while also presenting new positive Phase 3 clinical data for dapirolizumab pegol in systemic lupus erythematosus at the American College of Rheumatology Convergence 2025 in Chicago.
• The new results suggest that dapirolizumab pegol is one of few biologics with positive late-stage data in global SLE studies, and the Vanqua agreement substantially expands Biogen’s immunology and inflammation portfolio.
• We'll assess how Biogen's expanded immunology pipeline, aided by the Vanqua licensing deal, affects its long-term investment case.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Biogen Investment Narrative Recap

To be a shareholder in Biogen today, you need confidence in its ability to drive future growth through successful late-stage drug development and expanding commercial launches, especially in areas like Alzheimer’s and lupus. The latest exclusive licensing of Vanqua Bio’s oral C5aR1 antagonist and new Phase 3 lupus data add breadth to Biogen’s immunology portfolio, but these headlines do not materially impact the most important short-term drivers, commercial performance of new launches and managing competitive pressures in core MS and specialty drug markets.

The announcement of positive Phase 3 results for dapirolizumab pegol in systemic lupus erythematosus stands out, as SLE is a highly competitive and underserved space where effective late-stage candidates are rare. This progress could support Biogen’s case for diversifying revenue streams and bolstering its pipeline, but it does not shift the immediate challenge of sustaining momentum for LEQEMBI, SKYCLARYS, and ZURZUVAE, where regulatory, commercial, or payer setbacks remain the key risk.

However, remember that despite a larger pipeline, the company’s future still hinges on a handful of new launches, and should one of them falter...

Biogen's outlook anticipates $9.4 billion in revenue and $2.1 billion in earnings by 2028. This scenario assumes a 2.1% annual revenue decline and a $0.6 billion increase in earnings from the current $1.5 billion.

Uncover how Biogen's forecasts yield a $172.34 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Seven fair value estimates from the Simply Wall St Community span US$100 to US$371, reflecting widely differing outlooks. At the same time, broadening competitive threats in MS, Alzheimer’s, and lupus remind us that company performance is not insulated from evolving market challenges, see how others are analyzing these key issues up close.

Explore 7 other fair value estimates on Biogen - why the stock might be worth over 2x more than the current price!

Build Your Own Biogen Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Biogen research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Biogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Biogen's overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.